<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor-A, is approved for the treatment of various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and its hematological toxicities are considered infrequent </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patient receiving chemotherapy (<z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>) plus bevacizumab developed <z:hpo ids='HP_0011009'>acute</z:hpo>, severe <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We postulated that this <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> could be directly triggered by bevacizumab </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A man with <z:e sem="disease" ids="C0677950" disease_type="Neoplastic Process" abbrv="">stage IV colorectal cancer</z:e> and synchronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> had received 10 cycles of FOLFOX plus bevacizumab (5 mg/kg) without significant hematological toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>Due to <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> was withdrawn after cycle 11 </plain></SENT>
<SENT sid="5" pm="."><plain>On cycle 12, shortly after bevacizumab infusion and before <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> infusion, the patient developed <z:hpo ids='HP_0001945'>fever</z:hpo>, lower limbs <z:hpo ids='HP_0000979'>purpura</z:hpo>, grade 1 proctorrhagia, and <z:hpo ids='HP_0000421'>epistaxis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Platelets had decreased from 105,000/mm(3) to 3000/mm(3) within 1 hour after bevacizumab infusion </plain></SENT>
<SENT sid="7" pm="."><plain>Flow cytometry identified platelet-associated immunoglobulins </plain></SENT>
<SENT sid="8" pm="."><plain>Despite 2 apheresis-derived platelet transfusions, oral corticotherapy, and gamma globulin infusions, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> persisted, but was finally successfully treated with a peptibody thrombopoietin mimetic, which was introduced 28 days after the last bevacizumab infusion </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Clinicians should keep in mind that bevacizumab can induce <z:hpo ids='HP_0011009'>acute</z:hpo> and potentially severe immune-mediated <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
</text></document>